| THIRD-PARTIES |
THIRD-PARTIES |
90%
|
Net revenue from Bio Supplies primarily consists of revenue related to biological products for non-therapeutic use and plasma sales to third parties. |
| AESKU-DIAGNOSTICS-GMBH |
AESKU-DIAGNOSTICS-GMBH |
85%
|
s for a few biological drugs, commonly used in the treatment of various inflammatory diseases, such as rheumatoid arthritis and ulcerative colitis. Progenika also co-developed with DIESSE Diagnostica… |
| ABT |
Abbott Laboratories |
72%
|
Reciprocal relationship from ABT graph: Reciprocal relationship from GIFLF graph: ither in late 2025 or early 2026 depending on approvals from regulatory authorities. In several countries, we distrib… |
| ABT |
Abbott Laboratories |
72%
|
ither in late 2025 or early 2026 depending on approvals from regulatory authorities. In several countries, we distribute BLOODchip ® blood group genotyping tests manufactured by our subsidiary Progen… |
| GRFS |
Grifols, S.A. |
72%
|
Millions of Euros Key management Other related Board of directors Associates personnel parties of the Company … |
| GRFS |
Grifols, S.A. |
72%
|
Reciprocal relationship from GRFS graph: Reciprocal relationship from GIFLF graph: Reciprocal relationship from GRFS graph: Reciprocal relationship from GIFLF graph: Reciprocal relationship from GRFS… |
| SNYNF |
Sanofi |
72%
|
cant decrease in the sales of any of these products, a significant decrease could result from plasma procurement and manufacturing issues resulting in lower product availability for sales and changin… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from GIFLF graph: cant decrease in the sales of any of these products, a significant decrease could result from plasma procurement an… |
| BIOTEST-AG |
BIOTEST-AG |
62%
|
ant influence over its interest in SRAAS at the closing of the transaction. The remaining 6.58 % stake in SRAAS shares is considered a financial asset valued at fair value with changes in “FV through… |
| BIOTEST-GMBH |
BIOTEST-GMBH |
62%
|
osure of confidential information, may be limited as to their term and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, our trade s… |
| BIOTEST-US-CORPORATION |
BIOTEST-US-CORPORATION |
62%
|
rged into our subsidiary Grifols Bio Supplies, Inc. 69 Table of Contents ● On December 28, 2018, our subsidiary GWWO, Biotest Pharmaceuticals Corporation (“BPCorp”), which is a subsidiary of BPC Plas… |
| BPC-PLASMA-INC-HAEMA-GMBH |
BPC-PLASMA-INC-HAEMA-GMBH |
62%
|
rged into our subsidiary Grifols Bio Supplies, Inc. 69 Table of Contents ● On December 28, 2018, our subsidiary GWWO, Biotest Pharmaceuticals Corporation (“BPCorp”), which is a subsidiary of BPC Plas… |
| BPL-PLASMA-INC |
BPL-PLASMA-INC |
62%
|
length basis. The CNMV also concluded that it had found no evidence that the financial indebtedness of Grifols as reflected in its financial statements does not comport with the facts. These conclusi… |
| CANADIAN-PLASMA-RESOURCES-CORPORATION |
CANADIAN-PLASMA-RESOURCES-CORPORATION |
62%
|
669 ( 16,997 ) 163,672 Consolidated profit for the year 180,669 ( 16,997 ) 163,672 Profit attributable to the Parent 59,315 ( 16,997 ) 42,318 Profit attributable to non-controlling interest N… |
| CMXHF |
CMXHF |
62%
|
Reciprocal relationship from CMXHF graph: Reciprocal relationship from GIFLF graph: . In addition to our four business units, we have other smaller operations, activities and business lines (“Others”… |
| CSL-GROUP |
CSL-GROUP |
62%
|
. In addition to our four business units, we have other smaller operations, activities and business lines (“Others”), which revenue primarily originates from the provision of manufacturing services t… |
| GOETECH-LLC |
GOETECH-LLC |
62%
|
34 191,305 F-34 Table of Contents GRIFOLS, S.A. AND SUBSIDIARIES Notes to the Consolidated Financial Statements (in thousand Euros) The amounts determined at the date of consolidation of the assets… |
| GRIFOLS-BIO-SUPPLIES-INC |
GRIFOLS-BIO-SUPPLIES-INC |
62%
|
s, based on a 2°C global warming scenario (SSP2-RCP-4.5). Additionally, we are developing a Decarbonization Plan that is expected to be published in 2026. We also estimated the potential financial im… |
| GRIFOLS-GROUP |
GRIFOLS-GROUP |
62%
|
CODM (2) Other material items F-44 Table of Contents GRIFOLS, S.A. AND SUBSIDIARIES Notes to the Consolidated Financial Statements (in thousand Euros) Millio… |
| GWWO-BIOTEST-PHARMACEUTICALS-CORPORATION |
GWWO-BIOTEST-PHARMACEUTICALS-CORPORATION |
62%
|
rged into our subsidiary Grifols Bio Supplies, Inc. 69 Table of Contents ● On December 28, 2018, our subsidiary GWWO, Biotest Pharmaceuticals Corporation (“BPCorp”), which is a subsidiary of BPC Plas… |
| HAEMA-AG |
HAEMA-AG |
62%
|
2022, as well as the consolidation method used in each case for preparation of the accompanying consolidated financial statements. Subsidiaries in which the Company directly or indirectly owns the ma… |
| HAEMA-GMBH |
HAEMA-GMBH |
62%
|
otes to the Consolidated Financial Statements (in thousand Euros) ● Grifols, through Grifols Shared Services North America, Inc. acts as guarantor of five plasma center lease agreements up to US Doll… |
| HAEMA-GMBH-BPC-PLASMA-INC |
HAEMA-GMBH-BPC-PLASMA-INC |
62%
|
rged into our subsidiary Grifols Bio Supplies, Inc. 69 Table of Contents ● On December 28, 2018, our subsidiary GWWO, Biotest Pharmaceuticals Corporation (“BPCorp”), which is a subsidiary of BPC Plas… |
| IMMUNOTEK-GH-LLC |
IMMUNOTEK-GH-LLC |
62%
|
atements. d) Changes in accounting criteria and corrections of error The financial information as of December 31, 2023 presented for comparative purposes, differs from that approved by the Ordinary G… |
| INTERSTATE-BLOOD-BANK-GROUP |
INTERSTATE-BLOOD-BANK-GROUP |
62%
|
Item 5 of this Part I, “Operating and Financial Review and Prospects—A. Operating Results—Factors Affecting Our Financial Condition and Results of Operations—Acquisitions.” ● In October 2020, we purc… |
| INTERSTATE-BLOOD-BANK-INC |
INTERSTATE-BLOOD-BANK-INC |
62%
|
ither in late 2025 or early 2026 depending on approvals from regulatory authorities. In several countries, we distribute BLOODchip ® blood group genotyping tests manufactured by our subsidiary Progen… |
| KEDPLASMA-LLC |
KEDPLASMA-LLC |
62%
|
length basis. The CNMV also concluded that it had found no evidence that the financial indebtedness of Grifols as reflected in its financial statements does not comport with the facts. These conclusi… |
| UNITED-STATES-THE-GRIFOLS-GROUP |
UNITED-STATES-THE-GRIFOLS-GROUP |
62%
|
ions. None of the withdrawn products involved reports of any significant impact on patients. We strongly believe that our safety philosophy is consistent with the business objective of generating pro… |
